Pharmaceutical heavyweight Mylan, the latest poster child for drug-industry greed, finally stuck up for itself Thursday. It argued that “the system,” not avarice, was to blame for the company jacking up the price of EpiPens, a common (and life-saving) allergy remedy, by over 400%.
“Look, no one’s more frustrated than me,” Mylan Chief Executive Heather Bresch declared on CNBC.
Also read: Instagram Just Keeps Growing Like Crazy
13:15 Alitalia expected to start bankruptcy procedures19
05:35 Arkansas carries out first execution since 2005 after Supreme Court denies stay requests22
05:18 The Latest: Inmate lost consciousness quickly, witnesses say27
05:18 Arkansas Puts Ledell Lee to Death, in Its First Execution Since 200527